187 1, n wasp inhibitor

Inhibits neural Wiskott-Aldrich syndrome protein (N-WASP) by stabilizing the autoinhibited state of the protein. Blocks phosphatidylinositol 4,5-bisphosphate (PIP2)-stimulated actin assembly (IC50 ~ 2 μM) but does not directly inhibit actin polymerization

187-1, N-WASP Inhibitor TFA, a 14-amino acid cyclic peptide, serves as an allosteric inhibitor of the neural Wiskott-Aldrich syndrome protein (N-WASP). This compound effectively suppresses actin assembly triggered by phosphatidylinositol 4,5-bisphosphate (PIP2), exhibiting a potent inhibitory concentration (IC 50) of 2 μM. Furthermore, 187-1, N-WASP Inhibitor TFA inhibits the activation of the Arp2 3 complex by N-WASP, maintaining the protein in its autoinhibited state, ensuring the prevention of its activation.

OXA (17-33) acetate is a more potent agonist of orexin-1 receptor (OX1, EC50 = 8.29 nM)) over OX2 (EC50 = 187 nM).

OXA(17-33) TFA is a potent and selective agonist for the orexin-1 receptor (OX1), with approximately 23-fold higher affinity for OX1 (EC50 = 8.29 nM) compared to the orexin-2 receptor (OX2) (187 nM) [1].

AC 187 TFA, a potent and orally active amylin receptor antagonist, exhibits an IC50 of 0.48 nM and a Ki of 0.275 nM. It demonstrates greater selectivity for the amylin receptor over calcitonin and CGRP receptors and has been shown to possess neuroprotective effects [1] [2].